TY - JOUR
T1 - Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact
AU - Galar, Alicia
AU - Valerio, Maricela
AU - Muñoz, Patricia
AU - Alcalá, Luis
AU - García-González, Xandra
AU - Burillo, Almudena
AU - Sanjurjo, María
AU - Grau, Santiago
AU - Bouza, Emilio
PY - 2017/1/1
Y1 - 2017/1/1
N2 - © 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.
AB - © 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.
KW - Drugs for Gram-positive bacteria
KW - Linezolid
KW - Therapeutic drug monitoring
U2 - 10.1128/AAC.00687-17
DO - 10.1128/AAC.00687-17
M3 - Article
VL - 61
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 10
ER -